HR 2665 delays Medicaid payment reductions for safety net hospitals by two years, changing the effective date from 2024 to 2026 under Section 1923(f)(7)(A) of the Social Security Act. This bill directly affects hospitals that serve high numbers of low-income and uninsured patients, providing them with additional time before facing reduced federal Medicaid payments. The key mechanism is a technical amendment to existing law, postponing an already scheduled payment adjustment without altering funding levels or eligibility. As a procedural bill, it does not create new programs or change hospital requirements.
This bill amends tax law to allow charitable organizations to fund collegiate housing projects without losing their tax-exempt status. Specifically, it permits 501(c)(3) charities to make grants for building, improving, or maintaining housing properties where full-time students live, as long as the housing is connected to a college or university. Grants cannot fund fitness facilities, and the bill clarifies that housing must primarily serve students (not incidental social activities). It directly affects charitable organizations and universities seeking tax-qualified funding for student housing infrastructure.
HJRES 53 seeks to block an Environmental Protection Agency (EPA) rule that would establish new emissions standards for heavy-duty vehicles like trucks and buses. If passed, the resolution would prevent the EPA's rule from taking effect by invoking a congressional disapproval process under Title 5 of U.S. law. The rule, published in the Federal Register on January 24, 2023, aimed to reduce air pollution from new heavy-duty engine standards. This disapproval would halt the implementation of those specific vehicle emissions requirements.
The PLUS for Veterans Act of 2023 clarifies and updates rules for veterans' benefit claims under the Department of Veterans Affairs. It sets a $12,500 annual fee cap (adjusted for inflation) for agents or attorneys representing veterans, prohibits charging fees for medical exams, and prohibits unauthorized fees with penalties including fines or up to one year in prison. The bill directly affects veterans seeking benefits, their legal representatives, and the VA by standardizing fee agreements, requiring VA reports on agent/attorney suspensions, and ensuring veterans can access free services from VA-recognized organizations. Key provisions include banning fees for medical reports and requiring clear fee disclosures to veterans.
HR 2630, the Safe Step Act, requires group health plans and health insurance issuers to establish a clear, transparent process for patients or their doctors to request exceptions to medication step therapy protocols. These protocols typically force patients to try cheaper drugs first before covering more expensive alternatives. The bill mandates that plans must approve exceptions when prior treatments failed, delay would cause serious harm, a treatment is unsafe, or a patient is stable on a previously approved drug, with strict 72-hour (or 24-hour in emergencies) decision timelines. It also requires plans to publish the exception process online and limit documentation requests to only necessary medical information. This law directly affects health insurers, employers offering health plans, and patients using step therapy for prescription drugs.
HR 2620, the Federal Firearms Licensee Protection Act of 2023, increases penalties for crimes targeting firearms licensees. It amends Section 924 of Title 18 to impose mandatory minimum sentences of 3 years for burglaries or 5 years for robberies committed at the business premises of licensed firearms dealers, manufacturers, or importers. The bill specifically targets violations of Section 922(u), which prohibits unauthorized access to these premises, and adds "attempts to do so" to the penalties. This directly affects licensed firearms businesses by strengthening legal protections against theft or violence at their locations. The law creates clearer, harsher consequences for crimes committed during burglaries or robberies at these specific business sites.
HR 2581, the ALVIN Act, prohibits all federal funding for the Manhattan District Attorney’s Office. It cancels unspent federal funds allocated to the office and requires the office to repay all federal money spent since January 1, 2022. The bill directly affects the Manhattan DA’s Office by cutting its federal financial support and mandating reimbursement for past expenses. It does not change any laws or policies but alters the funding relationship with the federal government.
Tax Fairness for Disaster Victims Act This bill allows individual taxpayers living in a disaster area to use earned income from a preceding taxable year for purposes of calculating the earned income tax credit. The bill applies if current year income is disrupted by a disaster and is less than the income of the preceding taxable year.
This bill terminates the national emergency declared by the President on March 13, 2020, under the National Emergencies Act. It ends the executive branch's authority to use emergency powers related to that specific declaration. The resolution passed both chambers in early 2023 and took effect April 10, 2023, without creating new policies or affecting specific groups.
Resident Physician Shortage Reduction Act of 2023 This bill increases the number of residency positions eligible for graduate medical education payments under Medicare for qualifying hospitals, including hospitals in rural areas and health professional shortage areas. Current law provides for an increase of up to 200 positions per fiscal year beginning in FY2023, with a total increase of 1,000 positions; each hospital may receive up to 25 additional positions. Current law also provides for an additional increase of up to 200 positions for FY2026, with at least 100 of these positions for psychiatry or related specialties; each hospital may receive up to 10 additional positions. The bill provides for an additional increase of 2,000 positions per fiscal year from FY2025-FY2031; during this period, each hospital may receive up to 75 additional positions in total under the bill and current law. Additionally, one-third of the positions that are made available under the bill must be allocated to hospitals that are already operating above applicable resident limits. The bill also requires the Government Accountability Office to report on strategies to increase the diversity of the health professional workforce, including with respect to representation from rural, low-income, and minority communities.
HR 2380, the Cellphone Jamming Reform Act of 2023, allows state and federal correctional facilities (like prisons and jails) to operate cellphone jamming systems to block wireless signals from contraband devices or communications involving individuals held in the facility. The bill restricts the Federal Communications Commission (FCC) from blocking such jamming systems, but requires facilities to limit jamming only to housing areas, have state facilities cover all costs, and consult with local law enforcement before implementation. It defines "jamming systems" broadly to include all necessary equipment and installation details. This bill directly affects correctional facilities seeking to prevent cell phone use by inmates, particularly for security purposes related to contraband. The law does not create new restrictions on cellphone use but changes how facilities can deploy jamming technology.
HR 1839, the Combating Illicit Xylazine Act, makes the illicit use and distribution of xylazine a federal crime by adding it to the Controlled Substances Act. The bill broadly defines xylazine to cover numerous chemical variants and prohibits human use or non-licit distribution, while preserving legitimate veterinary and pharmaceutical uses. It requires tracking xylazine in drug supply chains and mandates two reports to Congress within 1 and 4 years on its prevalence, sources, and whether it should be rescheduled. The bill directly affects individuals distributing or using xylazine illicitly, including as an additive to drugs like fentanyl, and aims to address its public health risks. Congress declared illicit xylazine an "emerging drug threat" under existing law.
